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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effectiveness of trigger point manual therapy for treating chronic non-cancer pain in adults.
B A C K G R O U N D
Description of the condition
Chronic pain has long been defined as pain that persists beyond the
healing time needed to recover from an injury (Patterson 2003),
and often for longer than sixmonths (Elkins 2007; Keefe 1982). In
contrastwith acute pain, chronic painmay communicate very little
about an associated or underlying disease process (Patterson 2003;
Chapman 1999). The International Association for the Study of
Pain (IASP) defines chronic pain as ’pain without apparent biolog-
ical value that has persisted beyond the normal tissue healing time
(usually taken to be 3 months)’ (Harstall 2003). For the purposes
of our review, we will use the IASP definition of chronic pain; that
is, pain that has persisted beyond threemonths following an initial
injury.
Myofascial pain (MP) is a formof pain that is thought to arise from
myofascial trigger points (TrPs). Myofascia consists of muscle and
the highly innervated connective tissue that surrounds it. TrPs are
commonly thought of as taut bands within muscle that are usu-
ally painful to palpation, reproduce the patient’s symptoms, and
cause referred pain (Borg-Stein 2002). The four most commonly
used clinical criteria to define TrPs according to Tough 2007 are
i) a tender spot in a taut band of skeletal muscle, ii) patient pain
recognition, iii) predicted pain referral pattern and iv) local twitch
response.MP can be acute and chronic in presentation. It is a com-
monly diagnosed disorder that is thought to be caused by muscle
injury, overuse or repetitive strain (Bennett 2007). Incidence re-
porting varies from 30% to 93% in clinics of different specialities
and pain management centres (Cummings 2007; Fishbain 1986;
Fricton 1985; Han 1997; Skootsky 1989).
There is controversy in the literature regarding the existence, clin-
ical significance and underlying mechanisms behind TrPs. Tradi-
tionally the focus has been on peripheral mechanisms underlying
the condition. It has been postulated that abnormal neurophys-
iology and a perturbed biochemical milieu are relevant to TrPs
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(Bennett 2007). There is some evidence that TrPs may be associ-
ated with increased release of acetylcholine by the nerve terminal
of an abnormal motor endplate (Mense 2003, Simons 2002). In-
creased release of acetylcholine can result in sustained depolarisa-
tion of the postjunctional membrane of the muscle fibre and pro-
duce sustained sarcomere shortening and contracture. It is thought
that this may greatly increase local energy consumption and re-
duce local circulation that produces local ischemia and hypoxia.
Mechanical, chemical, or other noxious stimuli or injury may me-
diate the abnormal release of acetylcholine (Liley 1956). When
compared to normal muscle, some studies suggest that the active
TrPs have an acidic pH environment and elevated levels of several
biologically relevant molecules such as tumour necrosis factor-al-
pha (TNFα), interleukin-1b, calcitonin-gene-related polypeptide
(CGRP), substance P, bradykinin, serotonin and norepinephrine
(Shah 2005). It is hypothesised that these active factors might
also stimulate the local autonomic nervous system fibres to release
more acetylcholine, completing a ’positive feedback loop’ (Mense
2001; Simons 1999).
More recently research is moving towards central mechanisms be-
hind the condition (Fernández-de-las-Peñas 2013). Referred pain,
the most characteristic sign of TrPs, is thought by some to be a
central phenomenon initiated and activated by peripheral sensi-
tisation, whereby the peripheral nociceptive input from the mus-
cle can sensitise dorsal horn neurons that were previously silent
(Fernández-de-las-Peñas 2013). TrPs are seen by some as a pe-
ripheral source of nociception that can act as ongoing nocicep-
tive stimuli contributing to pain propagation and widespread pain
(Fernández-de-las-Peñas 2013). The precise pathophysiological
basis of MP remains unclear and a definitive explanation has yet
to be agreed.
There is controversy in the literature regarding the assessment of
TrPs (Fernández-de-las-Peñas 2013; Tough 2007; Wolfe 1992).
TrPs are predominantly identified and diagnosed by palpation al-
though the reliability of this is questioned in the literature (Lucas
2009Wolfe 1992). It is unclearwhether professional training or ex-
pertise improves ability to palpate or diagnose TrPs (Wolfe 1992).
Patients may experience pain, and may also experience difficulties
due to the pain including inability to work, mood changes, and
reduced quality of life (Borg-Stein 2002). In most cases, the dis-
comfort usually resolves in a few weeks without medical interven-
tion. When the pain persists or worsens and becomes chronic, it is
referred to as a myofascial pain syndrome (MPS) (Bennett 2007;
Borg-Stein 2002).
Many pharmacologic and nonpharmacologic treatments are used
in themanagement of TrPs associatedwithMP.Drugs such as anal-
gesics (e.g. tramadol), non-steroidal anti-inflammatory drugs, tri-
cyclic antidepressants (e.g. amitriptyline), alpha-2 adrenergic ago-
nists (such as tizanidine), and anticonvulsant drugs are commonly
used. Recently, botulinum toxin has also been used for the treat-
ment of MP (Bennett 2007; Borg-Stein 2002; Borg-Stein 2006;
Fleckenstein 2010; Leite 2009; Soares 2012). However, the effec-
tiveness of medication can often be unsatisfactory and side effects
are common.More targeted therapies include trigger pointmanual
therapy (TPMT), acupuncture, dry needling, local injection, low-
power laser, muscle-stretching technique, andmassage (Borg-Stein
2002; Borg-Stein 2006; Renan-Ordine 2011; Sun 2010; Tough
2009).
In a systematic review of acupuncture and dry needling for the
management of TrP pain (Tough 2009) the authors concluded that
there was limited evidence that deep needling directly into TrPs
has an overall treatment effect when compared with standardised
care. They also suggested that there was no logical basis for choos-
ing the optimal intervention for MP until different interventions
were compared directly. Currently there are no systematic reviews
comparing the effects of manual therapy in the form of TPMT
with dry needling, acupuncture or other forms of TrP treatment.
The current review aims to redress this and will focus on TPMT.
Description of the intervention
For the purposes of this review we will define TPMT as treatment
that involves the manual application of pressure, usually sustained
digital pressure, but may include the use of devices (for example
the Jacknobber ® or Knobble ® ) to apply pressure to the TrPs. We
will not consider devices that penetrate the skin such as acupunc-
ture needles as a form of TPMT but we may include them in this
review as possible comparisons with TPMT. The therapist may
place the muscle containing the trigger point into positions of
longitudinal tension or stretch whilst performing the TPMT. The
optimal duration of applied pressure, patient positioning and fre-
quency of treatments is at present not clearly reported or defined
in the literature. We will not include treatments with more gen-
eral effects that are not specifically addressing the TrP, including
transverse friction massage, muscle energy techniques, mobilisa-
tion, massage, manipulations, and spray and stretch.
How the intervention might work
The proposedmechanisms of the proposed effect of TPMT, or any
form of treatment to TrPs, is poorly understood at present. Expla-
nations tend to focus on a peripherally maintained model of pain.
Ischaemic compression is themost cited theory used to explain the
effect of TPMT. It is thought that the application of pressure to a
TrP produces ischaemia that ablates the TrP (Lavelle 2007; Simons
1999). Theories relating to the effect on the central nervous system
have been postulated previously, for example D’Ambrogio 1997
described adjustments to pain threshold in the spinal cord follow-
ing TPMT. There is growing interest in the central mechanisms
behind TrPs and their treatment (Fernández-de-las-Peñas 2013).
Why it is important to do this review
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No ’gold standard’ of management has been suggested for chronic
non-cancer pain, including MP. The benefits of TPMT remain
controversial (Tough 2009). It has been suggested that treatment
of TrPs may not be appropriate for chronic pain conditions, be-
ing more suitable for conditions such as whiplash associated dis-
order or ’sustained postural strain’ (Tough 2009 ). A systematic
review of the evidence from randomised clinical trials (RCTs) for
the effectiveness of TPMT may assist patients with their choice
and expectations of treatments, help clinicians in their treatment
choices, and inform future clinical guidelines that may be of use
to policymakers and those who commission health care.
O B J E C T I V E S
To determine the effectiveness of trigger point manual therapy for
treating chronic non-cancer pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs (including those of parallel, cluster-ran-
domised and cross-over design) published in any language. We
will translate studies published in a language other than English.
To reduce risk of bias we will exclude studies in which participants
were not randomised to intervention groups . We will include
studies regardless of publication status.
Types of participants
We will include all studies of adults, 18 years of age or over, with
chronic non-cancer pain presentations. We will exclude studies of
headaches and progressive neurological conditions. We anticipate
predominantly musculoskeletal, back pain, pelvic pain and facial
pain patient groups although we will not limit to these groups if
appropriate.
For the purposes of this review we define chronic pain as pain
of greater than three months’ duration. Where studies include
patients with pain of both longer and shorter than three months’
duration, and it is possible to distinguish the results from both
groups, thenwe will include the data from the chronic pain group.
Types of interventions
We will include all comparisons of manual therapy interventions,
as described in the Description of the intervention above, em-
ployed in either a stand-alone fashion or in combination where
the only difference between the active group and the compar-
ison group is TPMT, compared with placebo, no treatment or
another intervention, or of varying interventions compared with
each other, which are aimed at treating pain or disability, or both,
associated with TrPs.
Due to anticipated heterogeneity of modes of delivery and of ther-
apists delivering, we will accept any reported delivery of the inter-
vention but we anticipate predominantly qualified manual thera-
pists including physiotherapists, osteopaths and chiropractors. We
will not apply restrictions on the duration of the intervention or
the frequency with which it is delivered because optimal treatment
dose is not clearly defined in the literature. We will include mul-
timodal interventions where TPMT is separately analysed.
Wewill include studies that include sham interventions as controls
, however given the difficulty of delivering sham TPR treatment,
control conditions can also include
• no treatment or waiting list control,
• any active treatments such as standard manual therapy,
standard physiotherapy, stretch, acupuncture, rehabilitative and
psychological interventions,
• drug therapies, including TrP injections.
Types of outcome measures
Primary outcomes
1. Changes in pain severity/intensity as measured using a
visual analogue scale (VAS), numerical rating scale (NRS), verbal
rating scale or Likert scale. For the purposes of this review we
will define moderate change as between 30% and 49% change
on NRS, and substantial change will be considered to be 50% or
greater improvement from baseline (Dworkin 2008).
2. Adverse events such as drop outs or reports of pain
worsening.
We will present and analyse primary outcomes as change on a
continuous scale or in a dichotomised format as the proportion of
participants in each group who attained a predetermined thresh-
old of improvement. For example, we will judge cut-points from
which to interpret the likely clinical importance of (pooled) effect
sizes according to provisional criteria proposed in the IMMPACT
consensus statement (Dworkin 2008).
Secondary outcomes
1. Health-related quality of life (HR-QOL).
2. Changes in functional ability as measured by validated
questionnaires/scales such as the Brief Pain Inventory (BPI)
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interference scale (minimum 1 point change) or functional
testing protocol.
3. Physiotherapy measures such as range of movement,
strength.
4. Reductions in healthcare use, including medication, visits
to primary or secondary care.
5. Self-efficacy for activity such as the Pain Self Efficacy
Questionnaire (PSEQ)
6. Outcomes such as satisfaction or overall improvement
We will present and analyse secondary outcomes as change on a
continuous scale or in a dichotomised format. For example, equiv-
alent measures of treatment effect with respect to patient’s global
impression of change (PGIC) have been defined as ’much’ im-
proved (moderate benefit) and ’very much’ improved (substantial
benefit) (Dworkin 2008).
Search methods for identification of studies
Electronic searches
We will search the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL, latest issue);
• Ovid MEDLINE (1946 to present);
• Ovid EMBASE (1974 to present);
• EBSCO CINAHL (1982 to present);
• Ovid PsycINFO (1806 to present);
• Ovid AMED (1985 to present);
• LILACS (1986 to present);
• PEDro (1929 to present);
• Web of Science (ISI) (1970 to present);
• SciVerse SCOPUS (1823 to present);
• Database of Abstracts of Reviews of Effects (DARE), The
Cochrane Library (1994 to present);
• Health Technology Assessments (1994 to present);
We will use the search strategy shown in Appendix 1 to search
MEDLINE,amend where necessary, to search the other databases
listed. We will apply no language or date restrictions.
Searching other resources
We will review the bibliographies and reference lists of any RCTs
and review articles identified, contact the authors of unpub-
lished work, search the websites of researchers active in the area,
and search www.clinicaltrials.gov and apps.who.int/trialsearch/ to
identify additional published or unpublished data.
Data collection and analysis
Selection of studies
Two review authors (DD and KP) will determine eligibility by
reading the title and abstract of studies identified by the search.
Studies that clearly do not satisfy inclusion criteria will be elim-
inated, and we will obtain full copies of the remaining studies.
Two review authors (DD and KP) will read these studies indepen-
dently and reach agreement by discussion. A third author (SB) will
be consulted in case of disagreement. We will not anonymise the
studies in any way before assessment. We will include a PRISMA
study flow diagram in the full review (Liberati 2009) to document
the screening process, as recommended in the Cochrane Hand-
book (Higgins 2011a).
Data extraction and management
Two review authors (SB and SH) will independently extract data
using a standard form which we will pilot. We will check for
agreement before entry into RevMan 5 (RevMan 2014). We will
include information about:
• the pain condition and number of participants treated
• the method of delivery of the intervention and details of the
clinician applying the treatment where stated;
• the frequency and duration of treatment;
• study design (placebo or active control);
• study duration and follow-up;
• analgesic outcome measures and results;
• withdrawals and adverse events (participants experiencing
any adverse event or serious adverse event),
• location (country) and study environment;
• any declarations of interest.
Assessment of risk of bias in included studies
Two review authors (RML and SH) will independently assess risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b)
and adapted from those used by the Cochrane Pregnancy and
Childbirth Group, with any disagreements resolved by discussion.
If this is not possible then we will consult a third reviewer (DD).
We will assess the following for each study.
• Random sequence generation (checking for possible
selection bias). We will assess the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated), high risk of bias (studies using a
non-random process, e.g. odd or even date of birth; hospital or
clinic record number. We will exclude studies at high risk of bias.
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• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
before assignment determines whether intervention allocation
could have been foreseen in advance of or during recruitment, or
changed after assignment. We will assess the methods as: low risk
of bias (e.g. telephone or central randomisation; consecutively
numbered sealed opaque envelopes); unclear risk of bias (method
not clearly stated); high risk of bias (studies that do not conceal
allocation e.g. open list). We will exclude studies at high risk of
bias.
• Blinding of outcome assessment (checking for possible
detection bias). Due to the nature of the intervention being
reviewed it is extremely unlikely that there will be double-
blinded trials. Where studies have included blinding we will
assess the methods used to blind study participants and outcome
assessors from knowledge of which intervention a participant
received. We will assess the methods as: low risk of bias (study
states that it was blinded and describes the method used to
achieve blinding); unclear risk of bias (study states that it was
blinded but does not provide an adequate description of how this
was achieved). High risk of bias (We will judge unblinded studies
as high risk of bias unless they demonstrate (for uncertain or low
risk of bias) equivalence of patient expectation of benefit and
equivalence of therapist allegiance and skills across conditions.
We will note this in the ’Summary of findings’ table).
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We will assess the methods used to deal with
incomplete data as: low risk of bias (< 10% of participants did
not complete the study or used ‘baseline observation carried
forward’ analysis, or both); unclear risk of bias (method not
clearly stated); high risk of bias (used ’last observation carried
forward’ analysis’ or ’completer’ analysis).
• Size of study (checking for possible biases confounded by
small size). We will assess studies as being at low risk of bias (≥
200 participants per treatment arm); unclear risk of bias (50 to
199 participants per treatment arm); high risk of bias (< 50
participants per treatment arm).
Measures of treatment effect
We will present treatment effect sizes using appropriate metrics.
We will calculate risk ratio (RR) with 95% confidence inter-
vals (CIs) for dichotomised outcome measures.We will calculate
the number needed to treat for an additional beneficial outcome
(NNTB) as an absolute measure of treatment effect where possi-
ble.
We will express the size of treatment effect on pain intensity, as
measured with a VAS or NRS, using the mean difference (MD)
(where all studies utilised the same measurement scale) or the
standardised mean difference (SMD) (where studies used different
scales). In order to aid interpretation of the pooled effect size we
will back-transform the SMD to a 0 to 100 mm VAS format on
the basis of the mean standard deviation from trials using a 0 to
100 mm VAS where possible.
Unit of analysis issues
If there is more than one treatment arm, we will combine them
where they represent sufficiently similar treatment; otherwise two
review authors, SH and RML will independently decide which
best represents the treatment under scrutiny. They will refer dis-
agreements to a third reviewer (DD).
Where cross-over design trials are included we will analyse the first
phase only.
In the case of cluster RCTs we plan to meta-analyse the effect
estimates and their standard errors from analysis using the generic
inverse-variance method in RevMan 2014 as recommended by the
Cochrane Handbook, section 9.4.3 (Deeks 2011). Where data
allowwe plan to adjust for the effects of clusteringusing an estimate
of the intracluster (or intraclass) correlation coefficient (ICC) as
per Cochrane Handbook recommendations in section 16.3.4 (
Higgins 2011c) .
Dealing with missing data
Where information is missing from the included studies, we will
contact the study authors to provide additional information.
Assessment of heterogeneity
Clinical heterogeneity will be dealt with by attempting to combine
studies that examine similar conditions (e.g. pelvic pain, chronic
low back pain) or therapists (e.g. physiotherapists, chiropractors).
We will assess heterogeneity using the Chi2 test to investigate the
statistical significance of such heterogeneity, and the l2 statistic
to estimate the amount of heterogeneity (Higgins 2003). Where
significant heterogeneity is present (we will use a P value of 0.1 as
the cut off value to determine significant heterogeneity), we will
explore subgroup analyses using pre-planned criteria as outlined
below in Subgroup analysis and investigation of heterogeneity.
Assessment of reporting biases
We will consider the possible influence of publication/small study
biases on review findings. Where possible, for studies that have
utilised dichotomised outcomes, we will test for the possible influ-
ence of publication bias on each outcome by estimating the num-
ber of participants in studies with zero effect required to change
the NNTB to an unacceptably high level (defined as an NNTB of
10), as outlined by Moore 2008.
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Data synthesis
Assuming significant clinical heterogeneity, we will use a random-
effects model for meta-analysis.
Where possible, wewill group extracted data according to duration
of effect.We will define short-term effects as those measured at less
than two weeks from the end of treatment; medium-term effects
as those that are recorded in the period between two weeks to three
months from the end of treatment; and long-term effects as those
measured at more than three months post-treatment.
Where inadequate data are found we will perform narrative syn-
thesis of the evidence using the GRADE system, as described in
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Schünemann 2011).
Subgroup analysis and investigation of heterogeneity
1. If there are sufficient trials, we plan to analyse those with
baseline pain <30/100 and >30/100 and Y studies separately,
because clinical utility depends on effects not being restricted to
relatively mild pain intensity.
2. We plan subgroup analysis, where there are sufficient
numbers of studies, according to practitioner, such as
physiotherapists, osteopaths, chiropractors, physicians.
3. We plan subgroup analysis of studies according to type of
pain if there are sufficient for meaningful groupings such as
pelvic pain, low back pain, widespread pain, facial pain
Sensitivity analysis
Where possible, we plan sensitivity analyses to assess the effect
of the different methodological decisions made throughout the
review process by removal of cluster RCTs to leave individually
randomised trials.
We will conduct sensitivity analyses on risk of bias where sufficient
data are available (investigating the influence of excluding studies
classified at high risk of bias).
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A P P E N D I C E S
Appendix 1. Medline Search Strategy
1. Trigger Points/
2. exp Myofascial Pain Syndromes/
3. (trigger point* or trigger site* or muscle knot*).tw.
4. (myofascial adj pain).tw.
5. or/1-4
6. exp Musculoskeletal Manipulations/
7. manual therap*.tw.
8. manipulative therap*.tw.
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23. (zone adj therap*).tw.
24. or/6-23
25. 5 and 24
26. exp Pain/
27. pain*.tw.
28. 26 or 27
29. 25 and 28
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